Danaher Corporation with ticker code (DHR) now have 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $310.00 and $236.00 calculating the mean target share price we have $284.62. (at the time of writing). Now with the previous closing price of $264.49 and the analysts are correct then there would likely be a percentage uptick in value of 7.6%. Also worth taking note is the 50 day moving average now sits at $260.88 while the 200 day moving average is $247.87. The market capitalization for the company is 191.18B. The price for the stock stands currently at: $264.71 USD
The potential market cap would be $205,727,238,952 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 48.57, revenue per share of $31.88 and a 3.98% return on assets.
Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. The Company’s segments include Biotechnology, which includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables and services; Life Sciences segment, which offers a range of instruments and consumables that are primarily used by customers to study the basic building blocks of life, including genes, proteins, metabolites, and cells, to understand the causes of disease, identify new therapies, and test and manufacture new drugs and vaccines; Diagnostics segment that offers clinical instruments, reagents, consumables, software, and services that hospitals, physicians’ offices, reference laboratories, and other critical care settings use to diagnose disease, and Environmental & Applied Solutions segment, which offers products and services that help protect precious resources and keep global food and water supplies safe.
